Journal of Kerman University of Medical Sciences

Prevalence of Alpha-1 Antitrypsin (A1AT) Deficiency among Patients with COPD in Kerman, Iran

Document Type : Original Article

Authors

Mitra Samareh Fekri 1
Sayed Mehdi Hashemi Bajgani 2
Nasrollah Jamshidi Gohari 3
Nasrin Bazargan Harandi 4
Mohammad Rahmatian 5

1 Associate Professor of Pulmonology‚ Cardiovascular Research Center‚ Institute of Basic and Clinical Physiology Sciences‚ Kerman University of Medical Sciences‚ Kerman‚ Iran

2 Assistant Professor of Pulmonology‚ Afzalipour Hospital Research Center‚ Kerman University of Medical Sciences‚ Kerman‚ Iran

3 General Medicine‚ Physiology Research Center, Institute of Basic and Clinical PhysiologySciences, Kerman University of Medical Sciences, Kerman, Iran

4 Assistant Professor of Pediatric Asthma and Allergy and Immunology‚ Afzalipour Hospital Research Center‚ Kerman University of Medical Sciences‚ Kerman‚ Iran

5 Vice Chancellor for Treatment‚ Kerman University of Medical Sciences, Kerman, Iran

Abstract
Background: One of the genetic risk factors for chronic obstructive pulmonary disease (COPD) is deficiency of Alpha-1 Antitrypsin (A1AT). There is no exact statistics about the prevalence of this disease in different regions of Iran. The present study aimed to determine the prevalence of alpha-1 antitrypsin (A1AT) deficiency in COPD patients in Kerman, Iran.
Methods: In the present study, the serum level of AAT in 294 COPD patients visited in the pulmonary clinic center in Kerman, Iran was measured. The diagnosis of COPD was confirmed through history taking and Spirometry before and after using Bronchodilator. Data analysis was done by using t-test and Chi-square test.
Results: Among294 studied patients, 223 individuals (75.9%) were male. None of the patients had absolute deficiency of A1AT, and only13 patients (4.4%) had a relative deficiency of A1AT. There was a statistically significant relationship between relative deficiency of A1AT and the severity of COPD in a way that in most of the cases, relative deficiency of this enzyme was associated with severe and very severe airway obstruction.
Conclusion: Based on the results of the present study and other similar studies in Iran, absolute and relative deficiency of A1AT in Iran has less frequency compared to other regions of the world and other factors such as cigarette smoking, opium addiction and consumption of fossil fuels have a more significant role in the prevalence of COPD in Iran.

Keywords

Alpha-1 Antitrypsin (A1AT)
Chronic Obstructive Pulmonary Disease (COPD)
Prevalence
  1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367(9524): 1747-57.
  2. Niederlander E. Cause of death in the EU. Statistics in focus - Population and social conditions. Eurostat, European Communities; 2006.
  3. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349(9064): 1498-504.
  4. Global Initiative for Chronic Obstructive Lung Disease [Internet]. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; [cited 2017 Jun 3].Available from: http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/.
  5. Siafakas NM. Definition and differential diagnosis of chronic obstructive pulmonary disease. In: Siafakas NM,editors. Management of Chronic Obstructive PulmonaryDisease. European Respiratory Society Monographs; 2006. P. 1-6.
  6. Lomas DA. The selective advantage of alpha1-antitrypsin deficiency. Am j respir crit care med 2006; 173(10):1072-7.
  7. Tishler PV, Carey VJ, Reed T, Fabsitz RR. The role of genotype in determining the effects of cigarette smokingon pulmonary function. Genet Epidemiol 2002; 22(3): 272-82.
  8. Viegi G, Pistelli F, Sherrill D, Maio S, Baldacci S, Carrozzi L. Definition, epidemiology and natural history of COPD. Eur Respir J 2007; 30(5): 993-1013.
  9. Crystal RG. Alpha 1-antitrypsin deficiency, emphysema, and liver disease. Genetic basis and strategies for therapy. JClin Invest 1990; 85(5): 1343-52.
  10. Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O, Ledue TB, Craig WY. Reference distributions for the positive acute phase serum proteins, alpha1-acid glycoprotein (orosomucoid), alpha1-antitrypsin, and haptoglobin: a practical, simple, and clinically relevant approach in a large cohort. J Clin Lab Anal 2000; 14(6): 284-92.
  11. Hill AT, Bayley DL, Campbell EJ, Hill SL, Stockley RA. Airways inflammation in chronic bronchitis: the effects of smoking and alpha1-antitrypsin deficiency. EurRespir J 2000; 15(5): 886-90.
  12. Greene CM, Hassan T, Molloy K, McElvaney NG. The role of proteases, endoplasmic reticulum stress and SERPINA1 heterozygosity in lung disease and α-1 anti-trypsin deficiency. Expert Rev Respir Med 2011; 5(3): 395-411.
  13. Nadi E, Hajilui M, S Abdoli S, Basiri Z. The Prevalence of the Alpha-1 Antitrypsin Deficiency in Patients with Chronic Obstructive Pulmonary Disease. Qom University of Medical Sciences Journal 2011; 5(1): 7-11.
  14. Brebner JA, Stockley RA. Recent advances in alpha-1 antitrypsin deficiency related lung disease. Expert Rev Respir Med 2013; 7(3):213-29.
  15. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003; 168(7): 818-900.
  16. Campose MA, Wanner A, Zhang G, Sandhaus RA. Trend in the diagnosis of symptomatic patients with Alpha-1 Antitrypsin deficiency between 1963 and 2003. Chest 2005; 128(3): 1179-86.
  17. Stoller JK, Brantly M, The challenge if detection Alpha-1 Antitrypsin deficiency. COPD 2013; 10(suppl 1): 26-34.
  18. Antonelli-Incalzi R, Imperiale C, Bellia V, Catalano F, Scichilone N, Pistelli R, et al. Do GOLD stages of COPD severity really correspond to differences in health status? Eur Respir J 2003; 22(3): 444-9.
  19. Dahl M, Nordestgaard BG, Lange P, Vestbo J, Tybjaerg-Hansen A. Molecular diagnosis of intermediate and severe alpha-l antitrypsin deficiency: MZ individuals with chronic obstructive pulmonary disease may have lower lung function than MM individuals. Clin Chem 2001; 47(1): 56-62.
  20. Rahaghi FF, Sandhaus RA, Rouhani F, Campos MA, Strange C, Hogarth DK, Eden E, Stocks JM, et al. The prevalence of alpha-1 antitrypsin deficiency among patients found to have airflow obstruction. COPD 2012; 9(4): 352-8.
  21. Carroll TP, O'Connor CA, Floyd O, McPartlin J, Kelleher DP, O'Brien G, et al. The prevalence of alpha-1 antitrypsin deficiency in Ireland. Respir Res 2011; 12: 91.
  22. Silverman EK, Sandhaus RA. Alpha1-antitrypsin deficiency. N Engl J Med 2009; 360(26): 2749-57.
  23. Kuca PJ, Campbell EJ, Bednarek M, Zielinski J, Tomkowski WZ. Prevalence of Alpha1-Antitrypsin Deficiency (AATD) In Patients with COPD in Poland. American journal of respiratory and critical care medicine. 2011; 183: A5354.
  24. Hogarth D, Sorroche P, Acquier MF, Wolfe K. Prevalence of AAT deficiency in COPD patients in argentina. Am J Respir Crit Care Med 2013; 187: A3678.
  25. Spínola C, Bruges-Armas J, Pereira C, Brehm A, Spínola H. Alpha-1-antitrypsin deficiency in Madeira (Portugal): the highest prevalence in the world. Respir med 2009; 103(10): 1498-502.
  26. Sitkauskiene B, Serapinas D, Blanco I, Fernández-Bustillo E, Janciauskiene S, Sakalauskas R. Screening for alpha1-antitrypsin deficiency in Lithuanian patients with COPD. Respir med 2008; 102(11): 1654-8.
  27. Garcia-Palenzuela R‚ Timiraos Carrasco R‚ Gomez-Besteiro ML, Lavia G, Lago Pose M, Lara B. Detection of alpha antitrypsin deficiency: A study on patients diagnosed with chronic obstructive pulmonary disease in primary health care. Semergen 2016 Jun25 doi :10.1016/J.Semergen Article in press.
  28. Aljarallah B, Ali A, Dowaidar M, Settin A. Prevalence of α-1-antitrypsin gene mutations in Saudi Arabia. Saudi J Gastroenterol 2011; 17(4):256-60.
  29. De Serres FJ, Blanco I, Fernández-Bustillo E. PI S and PI Z alpha-1 antitrypsin deficiency worldwide. A review of existing genetic epidemiological data. Monaldi Arch Chest Dis 2007; 67(4):184-208.
  30. Hutchison DC. Alpha 1-Antitrypsin Deficiency in Europe: geographical distribution of Pi Types S and Z. Respir Med 1998; 92(3):367-77.
  31. Geramizadeh B, Jowkar Z, Karami L, Masoumpour M, Mehrabi S, Ghayoumi MA. Alpha-1 antitrypsin deficiency in Iranian patients with chronic obstructive pulmonary disease. Iran Red Cresent Med J 2013; 15(11): e7508.

Journal of Kerman University of Medical Sciences
Volume 24, Issue 2
2017
Pages 103-110

Article View 7,702
PDF Download 16,184

Home

Editorial Board

Guide for Authors

Submit Manuscript

Guide for Reviewers

Contact Us